Results 161 to 170 of about 61,872 (307)

The hydrophobic C‐terminal sequence of transthyretin affects its catalytic kinetics towards amidated neuropeptide Y

FEBS Open Bio, 2019
Transthyretin (TTR) is a transporter for thyroid hormone and retinol binding protein that has recently been reported to have proteolytic activity against certain substrates, including amidated neuropeptide Y (NPY).
Sukanya Tangthavewattana, Ladda Leelawatwattana, Porntip Prapunpoj   +2 more
doaj   +1 more source

Plasma proteome correlates of lipid and lipoprotein: biomarkers of metabolic diversity and inflammation in children of rural Nepal. [PDF]

, 2019
Proteins involved in lipoprotein metabolism can modulate cardiovascular health. While often measured to assess adult metabolic diseases, little is known about the proteomes of lipoproteins and their relation to metabolic dysregulation and underlying ...
Christian, Parul, Cole, Robert N, Eroglu, Abdulkerim, Groopman, John, Lee, Sun Eun, Schulze, Kerry, Stewart, Christine P, West, Keith P, Wu, Lee S-F, Yager, James D   +9 more
core  

Left ventricular transthyretin amyloid load and apical sparing in patients with newly confirmed transthyretin amyloid cardiomyopathy

European Journal of Heart Failure, EarlyView.
In a large cohort of patients with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR‐CM), echocardiographic apical sparing was associated with increased left ventricular amyloid load and atrial remodelling. Quantitative biopsy analysis revealed that Perugini scores often failed to accurately reflect myocardial amyloid burden.
Thomas Krammer, Maria J. Baier, Vanessa Lutz, Anna‐Christina Hübner, Tilman Zschiedrich, David Lukas, Christian Le Phu, Matthias Wolf, Claire Maassen, Michael Wester, Stefan Neef, Christian Schach, Can‐Martin Sag, Katja Evert, Michael Paulus, Christine Meindl, Maria Tafelmeier, Kurt Debl, Lars S. Maier, Stefan Wagner, Christoph Röcken, Julian Mustroph   +21 more
wiley   +1 more source

Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy [PDF]

, 2022
Mario Nuvolone, M. E. Girelli, Giampaolo Merlini   +2 more
openalex   +1 more source

Urinary markers in heart failure – types, timing and thresholds. European Journal of Heart Failure expert consensus document

European Journal of Heart Failure, EarlyView.
Pathophysiologic mechanisms of heart failure (HF) (i.e. renin–angiotensin–aldosterone system [RAAS], congestion, and inflammation), together with patient‐related factors such as diabetes, hypertension, and chronic kidney disease (CKD), contribute to kidney function decline and glomerular or tubular injury.
Masatake Kobayashi, Biykem Bozkurt, Peder Langeland Myhre, Juan Carlos Lopez Azor, Mateusz Guzik, Gracjan Iwanek, Guillaume Baudry, Marta Cobo‐Marcos, Òscar Miró, Jeroen Dauw, Piotr Ponikowski, Wilfried Mullens, Alberto Palazzuoli, Marco Metra, Jan Biegus   +14 more
wiley   +1 more source

Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS‐B trial

European Journal of Heart Failure, EarlyView.
Summary of the HELIOS‐B trial design. Right: Forest (top) and spline (bottom) plots demonstrating the effect of vutrisiran versus placebo on clinical outcomes across age groups in HELIOS‐B. Age‐stratified outcomes with vutrisiran in transthyretin amyloid cardiomyopathy.
Awais Sheikh, Zi Michael Miao, Brian Claggett, Pablo Garcia‐Pavia, Francesco Cappelli, Emre Aldinc, Julian Gillmore, Scott D. Solomon, Marianna Fontana   +8 more
wiley   +1 more source

Oxidative damage in immunoglobulin light chain and transthyretin cardiac amyloidosis – a closer look

Redox Experimental Medicine
Heart failure is a progressive disease, representing a growing cause of morbidity, hospitalization, and mortality. An increasingly common type of heart failure with preserved ejection fraction (HFpEF) is an immunoglobulin light chain and transthyretin ...
Elena Cavallone, Amir Hassan Mousavi, Carloalberto Biolé, Giulia Nangeroni, Alessandra Chinaglia, Matteo Bianco   +5 more
doaj   +1 more source

Microvascular obstruction in cardiac amyloidosis

European Journal of Heart Failure, EarlyView.
Lucrezia Netti, Adam Ioannou, Ana Martinez‐Naharro, Yousuf Razvi, Aldostefano Porcari, Lucia Venneri, Viviana Maestrini, Dan Knight, Ruta Virsinskaite, Muhammad U. Rauf, Tushar Kotecha, Rishi K. Patel, Ashutosh Wechelakar, Helen Lachmann, Peter Kellman, Charlotte Manisty, James Moon, Philip N. Hawkins, Julian D. Gillmore, Marianna Fontana   +19 more
wiley   +1 more source

A clinical case of transthyretin amyloidosis with manifestations of seronegative arthritis

Klinicist
Introduction. A clinical case of an 80-year-old patient with clinical and instrumental manifestations of amyloidosis caused by the deposition of non-mutant (“wild type”) transthyretin (Amyloidosis “wild type” TransThyRetin, ATTRwt) is described.
V. A. Mareeva, A. A. Klimenko, E. R. Moskalets, P. A. Glazunov, N. A. Shostak, E. V. Zhilyaev   +5 more
doaj   +1 more source

Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis

, 2020
Jennifer Kollmer, Ute Hegenbart, Christoph Kimmich, Ernst Hund, Jan Purrucker, John M. Hayes, Stephen I. Lentz, Georges Sam, Johann M. E. Jende, Stefan Schönland, Martin Bendszus, Sabine Heiland, Markus Weiler   +12 more
openalex   +1 more source